Revvity Partners with Eli Lilly to Launch AI Drug Discovery Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: NASDAQ.COM
- Collaborative Innovation: Revvity's partnership with Eli Lilly integrates Lilly's AI-driven predictive modeling platform, Lilly TuneLab, into the Revvity Signals platform, aiming to expand access to advanced AI tools for drug discovery and enhance research efficiency.
- Data Security Assurance: The collaboration establishes a scalable federated framework that allows biotech companies to apply Lilly's predictive models to their research programs while keeping proprietary data private and secure, ensuring both data confidentiality and research flexibility.
- Funding Support Initiative: Revvity and Lilly will jointly fund access for selected participants, including the use of Signals One and Signals Xynthetica software along with modeling credits, aiming to lower barriers to AI adoption across the biotech sector and promote technology proliferation.
- Integration Advantage: Lilly TuneLab offers AI and machine learning models trained on decades of Lilly research data, enhanced through federated learning, while Revvity's Signals platform integrates these models into existing scientific workflows, significantly boosting overall drug discovery efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1191.740
Low
950.00
Averages
1192
High
1500
Current: 1191.740
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
Viking's VK2735 Drug Shows Promising Outlook
- Clinical Trial Progress: Viking's VK2735 demonstrated a steeper weight loss rate in Phase 2 trials, leading to investor optimism for its Phase 3 results expected in 2027 and 2028, which could significantly boost the company's stock price.
- Dual-Formulation Advantage: As a dual-formulation therapy, VK2735's initial injectable dose aims for rapid weight loss, followed by an oral maintenance dose, potentially enhancing patient adherence and treatment efficacy, thus strengthening its market competitiveness.
- New Drug Development: Viking has also initiated a Phase 1 study for VK3019, a novel dual amylin and calcitonin receptor agonist, showcasing the company's diverse potential in the weight-loss drug sector, which may attract more investor interest.
- Positive Market Reaction: In June, Viking Therapeutics' stock rose by 19.2%, reflecting market optimism regarding its drug pipeline, particularly in innovative weight-loss solutions and potential returns.
See More
Stocks Close Lower as AI Trade Volatility Increases
- Market Pullback: Stocks closed lower to end the holiday-shortened trading week, although the S&P 500 rebounded by about 1.5% after last week's decline, indicating short-term market volatility.
- Employment Data Impact: A soft June jobs report eased concerns about the Federal Reserve raising interest rates in the coming months, potentially providing some confidence to investors, yet the overall market remains affected by AI trade volatility.
- Portfolio Performance: This week, stocks in the portfolio such as Corning, Arm Holdings, and Intel faced pressure due to changing market sentiment, while software companies like Salesforce and Microsoft saw gains, both up nearly 5% for the week.
- Economic Data Preview: Next week will feature several important economic updates, including service sector activity reports and mortgage applications, which investors should monitor for their potential impact on the market.
See More
Eli Lilly Stock Surges on Strong Drug Approvals and Market Position
- Stock Surge: Eli Lilly's stock has risen approximately 6.7% over the past week, driven by strong company-specific news and a broader rally in the U.S. drug and biotech sectors, reflecting market confidence in its growth prospects.
- Drug Approval Recommendation: The European Medicines Agency's Committee recommended approval of Lilly's Jaypirca for chronic lymphocytic leukemia treatment, which, if approved, would expand its indication in the EU, with a final decision expected in one to two months, potentially boosting revenue.
- Medicare Program Launch: Lilly announced its GLP-1 Bridge program, set to provide eligible Medicare Part D beneficiaries access to its oral GLP-1 drug Foundayo and injection Zepbound for $50 per month starting July 1, 2026, marking the first broad Medicare coverage for GLP-1 obesity medications.
- Market Leadership: Lilly maintains a strong position in the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, expected to benefit from rising global demand for GLP-1 therapies, despite challenges from price declines and increasing competition.
See More
Medicare Begins Coverage for Obesity Drugs
- Policy Shift: Medicare's new temporary program covers obesity drugs for the first time, potentially enabling millions of older Americans to afford GLP-1 medications from Novo Nordisk and Eli Lilly, significantly improving their health outcomes and quality of life.
- Patient Education Initiatives: Walmart and CVS Health have launched a nationwide effort at nearly 5,000 locations to provide educational materials and pharmacy support, addressing the fact that 82% of older Americans were unaware of the new coverage, thereby enhancing patient engagement and understanding.
- Digital Tool Innovations: Walmart's Everyday Health Signals program helps seniors review their grocery purchases and recommend healthier alternatives, aiming to empower patients in managing their health and ensuring effective medication use.
- Pharmacy Professional Support: Pharmacists from Walmart and CVS will offer one-on-one consultations to assist patients in understanding treatment steps and managing side effects, particularly in medically underserved areas, thereby greatly enhancing patient care accessibility and experience.
See More
Medicare's New Policy Expands Access to Weight-Loss Drugs
- Market Access Expansion: Medicare's GLP-1 Bridge program allows seniors to access weight-loss drugs for a $50 monthly copayment, expected to significantly boost prescription volumes and drive market growth, particularly before 2027.
- Revenue Growth Expectations: Analysts project that the program could add over $1 billion in annual revenue for each of the leading companies, Eli Lilly and Novo Nordisk, with their market shares anticipated to remain stable at 60% and 40%, reflecting intensifying market competition.
- Changing Competitive Landscape: As companies like AstraZeneca, Pfizer, and Amgen develop their own GLP-1 drugs, the competitive dynamics are heating up, prompting investors to monitor these emerging players for potential investment opportunities.
- Oral Drug Popularity: The rising interest in oral GLP-1 formulations indicates that seniors are more likely to prefer pills over injections, which could further enhance market acceptance and drug proliferation.
See More
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
Viking's VK2735 Drug Shows Promising Outlook
- Clinical Trial Progress: Viking's VK2735 demonstrated a steeper weight loss rate in Phase 2 trials, leading to investor optimism for its Phase 3 results expected in 2027 and 2028, which could significantly boost the company's stock price.
- Dual-Formulation Advantage: As a dual-formulation therapy, VK2735's initial injectable dose aims for rapid weight loss, followed by an oral maintenance dose, potentially enhancing patient adherence and treatment efficacy, thus strengthening its market competitiveness.
- New Drug Development: Viking has also initiated a Phase 1 study for VK3019, a novel dual amylin and calcitonin receptor agonist, showcasing the company's diverse potential in the weight-loss drug sector, which may attract more investor interest.
- Positive Market Reaction: In June, Viking Therapeutics' stock rose by 19.2%, reflecting market optimism regarding its drug pipeline, particularly in innovative weight-loss solutions and potential returns.
See More
Stocks Close Lower as AI Trade Volatility Increases
- Market Pullback: Stocks closed lower to end the holiday-shortened trading week, although the S&P 500 rebounded by about 1.5% after last week's decline, indicating short-term market volatility.
- Employment Data Impact: A soft June jobs report eased concerns about the Federal Reserve raising interest rates in the coming months, potentially providing some confidence to investors, yet the overall market remains affected by AI trade volatility.
- Portfolio Performance: This week, stocks in the portfolio such as Corning, Arm Holdings, and Intel faced pressure due to changing market sentiment, while software companies like Salesforce and Microsoft saw gains, both up nearly 5% for the week.
- Economic Data Preview: Next week will feature several important economic updates, including service sector activity reports and mortgage applications, which investors should monitor for their potential impact on the market.
See More
Eli Lilly Stock Surges on Strong Drug Approvals and Market Position
- Stock Surge: Eli Lilly's stock has risen approximately 6.7% over the past week, driven by strong company-specific news and a broader rally in the U.S. drug and biotech sectors, reflecting market confidence in its growth prospects.
- Drug Approval Recommendation: The European Medicines Agency's Committee recommended approval of Lilly's Jaypirca for chronic lymphocytic leukemia treatment, which, if approved, would expand its indication in the EU, with a final decision expected in one to two months, potentially boosting revenue.
- Medicare Program Launch: Lilly announced its GLP-1 Bridge program, set to provide eligible Medicare Part D beneficiaries access to its oral GLP-1 drug Foundayo and injection Zepbound for $50 per month starting July 1, 2026, marking the first broad Medicare coverage for GLP-1 obesity medications.
- Market Leadership: Lilly maintains a strong position in the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, expected to benefit from rising global demand for GLP-1 therapies, despite challenges from price declines and increasing competition.
See More
Medicare Begins Coverage for Obesity Drugs
- Policy Shift: Medicare's new temporary program covers obesity drugs for the first time, potentially enabling millions of older Americans to afford GLP-1 medications from Novo Nordisk and Eli Lilly, significantly improving their health outcomes and quality of life.
- Patient Education Initiatives: Walmart and CVS Health have launched a nationwide effort at nearly 5,000 locations to provide educational materials and pharmacy support, addressing the fact that 82% of older Americans were unaware of the new coverage, thereby enhancing patient engagement and understanding.
- Digital Tool Innovations: Walmart's Everyday Health Signals program helps seniors review their grocery purchases and recommend healthier alternatives, aiming to empower patients in managing their health and ensuring effective medication use.
- Pharmacy Professional Support: Pharmacists from Walmart and CVS will offer one-on-one consultations to assist patients in understanding treatment steps and managing side effects, particularly in medically underserved areas, thereby greatly enhancing patient care accessibility and experience.
See More
Medicare's New Policy Expands Access to Weight-Loss Drugs
- Market Access Expansion: Medicare's GLP-1 Bridge program allows seniors to access weight-loss drugs for a $50 monthly copayment, expected to significantly boost prescription volumes and drive market growth, particularly before 2027.
- Revenue Growth Expectations: Analysts project that the program could add over $1 billion in annual revenue for each of the leading companies, Eli Lilly and Novo Nordisk, with their market shares anticipated to remain stable at 60% and 40%, reflecting intensifying market competition.
- Changing Competitive Landscape: As companies like AstraZeneca, Pfizer, and Amgen develop their own GLP-1 drugs, the competitive dynamics are heating up, prompting investors to monitor these emerging players for potential investment opportunities.
- Oral Drug Popularity: The rising interest in oral GLP-1 formulations indicates that seniors are more likely to prefer pills over injections, which could further enhance market acceptance and drug proliferation.
See More
